Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 122 pages | ID: C6901178AB52EN
Global Markets Direct

Abstracts

Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease – Drugs In Development, 2022, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 12, 1, 10 and 9 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Celiac Disease – Overview
Celiac Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease – Companies Involved in Therapeutics Development
Celiac Disease – Drug Profiles
Celiac Disease – Dormant Projects
Celiac Disease – Discontinued Products
Celiac Disease – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Celiac Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Celiac Disease – Pipeline by 9 Meters Biopharma Inc, 2022
Celiac Disease – Pipeline by Ahead Therapeutics SL, 2022
Celiac Disease – Pipeline by Allero Therapeutics BV, 2022
Celiac Disease – Pipeline by Amgen Inc, 2022
Celiac Disease – Pipeline by Amyra Biotech AG, 2022
Celiac Disease – Pipeline by Anokion SA, 2022
Celiac Disease – Pipeline by AnTolRx Inc, 2022
Celiac Disease – Pipeline by Calypso Biotech SA, 2022
Celiac Disease – Pipeline by Codexis Inc, 2022
Celiac Disease – Pipeline by Equillium Inc, 2022
Celiac Disease – Pipeline by Forte Biosciences Inc, 2022
Celiac Disease – Pipeline by GSK plc, 2022
Celiac Disease – Pipeline by ImCyse SA, 2022
Celiac Disease – Pipeline by Immunic Inc, 2022
Celiac Disease – Pipeline by ImmunogenX LLC, 2022
Celiac Disease – Pipeline by ImmunoMolecular Therapeutics LLC, 2022
Celiac Disease – Pipeline by ImmusanT Inc, 2022
Celiac Disease – Pipeline by JN Biosciences LLC, 2022
Celiac Disease – Pipeline by Johnson & Johnson, 2022
Celiac Disease – Pipeline by Mozart Therapeutics Inc, 2022
Celiac Disease – Pipeline by Nemysis Ltd, 2022
Celiac Disease – Pipeline by Parvus Therapeutics Inc, 2022
Celiac Disease – Pipeline by Pfizer Inc, 2022
Celiac Disease – Pipeline by Precigen Inc, 2022
Celiac Disease – Pipeline by Protagonist Therapeutics Inc, 2022
Celiac Disease – Pipeline by Provention Bio Inc, 2022
Celiac Disease – Pipeline by SQZ Biotechnologies Co, 2022
Celiac Disease – Pipeline by Synthetic Biologics Inc, 2022
Celiac Disease – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Celiac Disease – Pipeline by Theravance Biopharma Inc, 2022
Celiac Disease – Pipeline by Topas Therapeutics GmbH, 2022
Celiac Disease – Pipeline by Vactech Oy, 2022
Celiac Disease – Pipeline by Zedira GmbH, 2022
Celiac Disease – Dormant Projects, 2022
Celiac Disease – Dormant Projects, 2022 (Contd..1)
Celiac Disease – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Celiac Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022